Treatment of chronic hepatitis B and the implications of viral resistance to therapy

References

• Chen CJ, Yang HI, Su J et al.; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295(1), 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology130 (3), 678–686 (2006).
   PubMed Web of Science ®Google Scholar
• Tang B, Kruger WD, Chen G et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J. Med. Virol.72(1), 35–40 (2004).
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann. Intern. Med.135, 759–768 (2001).
   PubMed Web of Science ®Google Scholar
• Yang HI, Lu SN, Liaw YF et al.; Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med.347, 168–174 (2002).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut57(1), 84–90 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas HC. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J. Hepatol.47(4), 588–597 (2007).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology45(2), 507–539 (2007).
   PubMed Web of Science ®Google Scholar
• Cornberg M, Protzer U, Dollinger MM et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-)infection: upgrade of the guideline. Z. Gastroenterol.45(6), 525–574 (2007).
   PubMedGoogle Scholar
• Liaw YF, Sung JJ, Chow WC et al.; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351(15), 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P et al.; Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology40(4), 883–891 (2004).
   PubMed Web of Science ®Google Scholar
• Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon a for chronic hepatitis B. N. Engl. J. Med.334(22), 1422–1427 (1996).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Hepatology44, 548A (2006).
   Google Scholar
• Lau GK, Piratvisuth T, Luo KX et al.; Peginterferon α2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon a2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.352(26), 2682–2695 (2005).
   PubMed Web of Science ®Google Scholar
• Erhardt A, Blondin D, Hauck K et al. Response to interferon a is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut54(7), 1009–1013 (2005).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sevastianos V, Rapti I et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil treatment in HBeAg-negative chronic hepatitis B. Hepatology44, 213A (2006).
   Google Scholar
• Marcellin P, Lau GK, Bonino F et al.; Peginterferon α2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon α2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.351(12), 1206–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Bonino F, Lau GK et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon α2a (40kD) ± lamivudine: 3-year follow-up results. Presented at: 42nd Annual Meeting of the European Association for the Study of the Liver 2007. Barcelona, Spain, 11–15 April 2007 (Abstract 53).
   Google Scholar
• Lai CL, Gane E, Hsu CW et al. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology44, 222A (2006).
   Google Scholar
• Lai CL, Leung N, Teo EK et al.; Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology129(2), 528–536 (2005).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al.; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med.348(9), 808–816 (2003).
   PubMed Web of Science ®Google Scholar
• Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology43(6), 1385–1391 (2006).
   PubMed Web of Science ®Google Scholar
• Westland C, Delaney W 4th, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in Phase III studies of adefovir dipivoxil1. Gastroenterology125(1), 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Lampertico P, Marzano A, Levriero M et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative hepatitis B. Hepatology44, 693A (2006).
   Google Scholar
• Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology.133(5), 1445–1451 (2007).
   PubMed Web of Science ®Google Scholar
• Chang T, Gish R, De Man R. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.354, 1001–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Lai C, Shouval D, Lok A. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.354, 1011–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother.51(3), 902–911 (2007).
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology44(6), 1656–1665 (2006).
   PubMed Web of Science ®Google Scholar
• Reijnders JG, De Man RA, Pas SD, Schutten M, Janssen HL. Entecavir: a rescue therapy for chronic hepatitis B patients with a limited virological response to adefovir? Hepatology46(4 Suppl.1), 660A (2007) (Abstract 951).
   Google Scholar
• Núñez M, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS16, 2352–2354 (2002).
   PubMed Web of Science ®Google Scholar
• Nelson M, Portsmouth S, Stebbing J. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS17, F7–F10 (2003).
   PubMed Web of Science ®Google Scholar
• Van Bommel F, Wunsche T, Mauss S. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology40, 1421–1425 (2004).
   PubMed Web of Science ®Google Scholar
• Ristig M, Crippin J, Aberg J. Tenofovir disoproxil fumarate for chronic hepatitis B in HIV-coinfected individuals for whom interferon a and lamivudine therapy have failed. J. Infect. Dis.186, 1844–1847 (2002).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Fleury H, Trimoulet P. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology43, 548–555 (2006).
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Gane E, DeMan R et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174–0103. Hepatology46(4 Suppl. 1), 861A (2007) (Abstract LB6).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174–0102. Hepatology46(4 Suppl.1), 290A (2007) (Abstract LB2).
   Web of Science ®Google Scholar
• Schmutz G, Nelson M, Lutz T et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS20(15), 1951–1954 (2006).
   PubMed Web of Science ®Google Scholar
• Van Boemmel F, Zoellner B, Moeller B et al. Is tenofovir effective in treatment of adefovir resistant hepatitis B virus infections? Hepatology44, 567A (2006).
   Google Scholar
• Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol.48(3), 391–398 (2008).
   PubMed Web of Science ®Google Scholar
• Sung JJ, Lai JY, Zeuzem S et al. A randomised double-blind Phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patients with chronic hepatitis B: week 52 analysis. J. Hepatol.38(Suppl. 2), 25–26 (2003).
   Web of Science ®Google Scholar
• Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther.9(5), 679–693 (2004).
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology42, 1414–1419 (2005).
   PubMed Web of Science ®Google Scholar
• McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir – effects on HIV-1 replication and resistance. N. Engl. J. Med.356, 2614–2621 (2007).
   PubMed Web of Science ®Google Scholar
• Sheldon JA, Corral A, Rodés B et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS19(17), 2036–2038 (2005).
   PubMedGoogle Scholar
• Delaugerre C, Marcelin AG, Thibault V et al. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)–HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob. Agents Chemother.46(5), 1586–1588 (2008).
   Google Scholar
• Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology30(5), 1302–1306 (1999).
   PubMed Web of Science ®Google Scholar
• Matthews GV, Bartholomeusz A, Locarnini S et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS20(6), 863–870 (2006).
   PubMed Web of Science ®Google Scholar
• Sheldon J, Ramos B, Garcia-Samaniego J et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J. Acquir. Immune Defic. Syndr.46(3), 279–282 (2007).
   PubMedGoogle Scholar
• Lin CL, Tsai SL, Lee TH, Chien RN, Liao SK, Liaw YF. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut54 (1), 152–161 (2005).
   PubMedGoogle Scholar
• Lai CL, Gane E, Liaw YF et al.; Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med.357(25), 2576–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med.341, 1256–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology32, 847–851 (2000).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med.352, 2673–2681 (2005).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology131, 1743–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med.348, 800–807 (2003).
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med.339, 61–68 (1998).
   PubMed Web of Science ®Google Scholar
• Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis.36, 687–696 (2003).
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Hsu CW et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs lamivudine. Hepatology44, 222A (2006).
   Google Scholar
• Lai CL, Gane E, Liaw YF et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the international Phase III globe trial. Hepatology42, 748A (2005).
   PubMed Web of Science ®Google Scholar
• Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology43, 1385–1391 (2006).
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology125, 1714–1722 (2003).
   PubMed Web of Science ®Google Scholar
• Westland CE, Yang H, Delaney WE et al. Week 48 resistance surveillance in two Phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology38, 96–103 (2003).
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Rose RE, Pokornowski K et al. Assessment at three years show high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology44, 229A–230A (2003).
   Google Scholar